ARGX Stock Price and Chart — NASDAQ:ARGX — TradingView

Compare with argenx SE

Key stats

Upcoming earnings

Company info

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

ARGX bear case Bear case scenario H&S pattern forming on daily Bearisch div on weekly on multiple indicators Watch out for daily close below +-780. Important levels/zones: 780, 700-670, 530 55 bln market cap based on future growth. PE 93. (Quality healthcare sits around 10) bullish if big news/hard numbers 7/

ARGX Weekly Weekly Entry Points ARGX I dont like having to put a description in this

Argenx (ARGX) Analysis Company Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio b

by Richtv_official

Argenx Lead as Chugai's Muscle Disease Treatment Disappoints In a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the

Breakout trade in ARGX Argenx is another biotech stock setting up in a textbook breakout pattern. Shares traded up through resistance Monday morning on good volume, but the move was ultimately held back by a nasty overall market. ARGX still held up well, and will likely continue its advance higher.

$ARGX with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $ARGX after a Positive Under reaction following its earnings release placing the stock in drift D.

ARGX Bullish Trade Setup Looking to place some longs on ARGX. Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.n top 10: 10 8 25.0% 6 (0.35%) 6 (0.35%) 0.0% Funds Hol

by wallstreetsharks

Will ARGX break out ascending channel Will Argenx be Wall streets next Biotech unicorn? I am extremely bullish! Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry. Again great news for Argenx. 01feb2021 launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials

ARGX Buy Signal To Watch .After forming the gap at the market open , NASDAQ:ARGX has succeeded to close above the Red Line around the 206.5 . IF it succeeds today or in an upcoming day to close with bullish strength considerably above the green line at around the 217 mark ,I think It is likely to continue up to around th

by StockAnalystPro

argenx Announces Positive Topline Results from Phase 3 ADAPT Tri ARGX: argenx SE 2020-05-26 01:00:00 argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

An aggregate view of professional's ratings.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock

Weight3.80%

Market value‪407.71 M‬

Weight1.00%

Market value‪118.33 M‬

Weight3.63%

Market value‪106.10 M‬

Weight0.16%

Market value‪30.79 M‬

Weight1.82%

Market value‪22.89 M‬

Weight1.82%

Market value‪22.89 M‬

Weight4.68%

Market value‪22.25 M‬

Weight0.09%

Market value‪16.62 M‬

Weight1.41%

Market value‪16.58 M‬

Weight0.11%

Market value‪12.37 M‬

Weight0.27%

Market value‪11.39 M‬

Explore more ETFs